Lilly to Invest $364 Million in UK Biotech, Obesity Research
Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...
Daily Reporter1h
Why Lilly is pouring billions into LEAP
Lilly’s latest investment comes on the heels of three earlier rounds of manufacturing investment at the LEAP Research and ...
University of Manchester1h
New study to deepen understanding of a weight loss medication
Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking ...
Thousands of people with life-threatening obesity denied access to weight-loss jab Wegovy
Doctors have said access to the drug is a "postcode lottery" as Sky News analysis reveals just 800 people have been ...
‘Why doesn’t sliced bread have a warning on it? This is how I’d solve the obesity crisis’
There is no perfect definition of healthy or unhealthy food. There is no perfect system of regulation. But I believe that ...
Tory leadership hopeful Robert Jenrick urges overweight Brits to copy him and use Ozempic to shed the pounds if their doctor recommends the drug
The former immigration minister, who lost four stone in 12 months, said the drug had aided him at the start of his bid to ...
One MILLION overweight Brits will be paying for fat jabs like Ozempic by this time next year
Analysts say the number of private prescriptions for fat busting jabs like Ozempic in the UK are predicted to soar to over ...
pharmaphorum5h
FDA rethinking block on compounding of Lilly's obesity drug
The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...
Thousands denied weight loss jab due to slow NHS rollout - with some having to wait two years
Just 800 of the 13,500 patients eligible to start receiving Wegovy, which can help obese people lose 15% of their body weight ...
thedailyupside15h
Weight-Loss Drugs Might Not Tank Medicare After All
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
However, GLP-1-based therapies aren't going to be the only option in the weight loss medicines market forever. Some companies are pursuing other approaches that could be even more effective or ...